Published in
American Society of Hematology, Blood, 4(128), p. 519-528, 2016
DOI: 10.1182/blood-2015-11-683847
Links
- American Society of Hematology | PDF
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
Tools
Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
Journal article published in 2016 by
Marianna Sabatino,
Jinhui Hu,
Michele Sommariva,
Sanjivan Gautam,
Vicki Fellowes,
James D. Hocker,
Sean Dougherty,
Haiying Qin,
Christopher A. Klebanoff,
Terry J. Fry,
Ronald E. Gress,
James N. Kochenderfer,
David F. Stroncek,
Yun Ji,
Luca Gattinoni 
This paper is made freely available by the publisher.
Full text: Download
Preprint: archiving forbidden
Published version:
archiving forbidden
Data provided by 
Abstract
Key Points A platform for the generation of clinical-grade CD19-CAR–modified TSCM. CD19-CAR–modified TSCM mediate superior antitumor responses compared with CD19-CAR T cells currently used in clinical trials.